Thromb Haemost 2018; 118(08): 1488-1490
DOI: 10.1055/s-0038-1661391
Letter to the Editor
Georg Thieme Verlag KG Stuttgart · New York

Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature

Elodie Boissier
1  Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France
,
Steve Genebrier
2  Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France
,
Karim Lakhal
3  Anesthésie-Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France
,
Fabienne Nedelec-Gac
2  Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France
,
Marc Trossaërt
1  Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France
4  Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France
,
Catherine Ternisien
1  Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France
4  Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France
,
Isabelle Gouin-Thibault
2  Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France
› Author Affiliations
Further Information

Publication History

09 May 2018

24 May 2018

Publication Date:
30 June 2018 (online)

The advent of direct oral anticoagulants (DOACs) is a major breakthrough in the management of patients with venous thromboembolic diseases and atrial fibrillation. Clinical trials with DOACs have been performed without laboratory assessment, owing to their predictable anticoagulant response and wide therapeutic index. However, there are several circumstances in which assessment of DOAC effect may be desirable.[1] [2] [3] [4] Besides life-threatening situations in which an assay with rapid turnaround time may impact patient care, in settings such as extreme body weight, renal function impairment, gastrointestinal malabsorption, drug interactions or suspicion of overdose, a non-urgent measurement of DOAC may be needed.[1] [2] [3] [4] Only specific tests are deemed reliable to accurately measure DOAC concentrations but they are not widely available on a 24h/7d basis. Therefore, in non-urgent situations, samples may be transferred to a central laboratory and testing may be delayed for cost and workflow efficiency. To ensure precise and accurate measurements, both inappropriate storage conditions and the expiration of a time-limit before assaying the sample should be avoided. Nevertheless, precise data about storage conditions and maximum time before assaying the sample are lacking.

The aim of this study, performed in two university hospitals using different techniques, was to test whether rivaroxaban and apixaban plasmatic measurements are stable after being stored at room temperature up to 7 days after sampling.

Authors' Contributions

E. Boissier: conception and design, analysis and interpretation of the data, drafting and revision of the manuscript. S. Genebrier: data collection and revision of the manuscript. K. Lakhal: analysis and interpretation of the data and revision of the manuscript. F. Nedelec-Gac: data collection and revision of the manuscript. C. Ternisien: interpretation of the data and revision of the manuscript. I. Gouin-Thibault: conception and design, analysis and interpretation of the data, drafting and revision of the manuscript.